Nexentis unit MitoCareX adds Dan T. Major to scientific advisory board
NXTS•MitoCareX, a wholly owned Nexentis unit, added Bar-Ilan University chemistry professor Dan T. Major to its scientific advisory board to expand in silico drug-discovery capacity.
1. Advisory board appointment
MitoCareX said the appointment is intended to support evaluation and prioritization across its pipeline. The unit already uses computationally guided drug discovery, including an AI-driven collaboration with Boltz on biomolecular models and workflows.
